Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension
Open Access
- 27 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Human Genetics
- Vol. 15 (1), 18-22
- https://doi.org/10.1038/sj.ejhg.5201711
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Pulmonary Hypertension and Right Heart Failure in Pituitary Adenylate Cyclase–Activating Polypeptide Type I Receptor–Deficient MiceCirculation, 2004
- Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2004
- Genetic basis of pulmonary arterial hypertensionJournal of the American College of Cardiology, 2004
- Genetic Clues to the Cause of Primary Pulmonary HypertensionThe New England Journal of Medicine, 2001
- VIP Gene Transcription Is Regulated by Far Upstream Enhancer and Repressor ElementsBiochemical and Biophysical Research Communications, 2001
- Gene expression and transcript size of the prepro-peptide VIP/PHM-27 in normal human tissueNeuroscience Letters, 1993
- Complete Nucleotide Sequence of Human Vasoactive Intestinal Peptide/PHM‐27 Gene and Its Inducible PromoteraAnnals of the New York Academy of Sciences, 1988
- Studies toward the biosynthesis of vasoactive intestinal peptide (VIP)Peptides, 1984
- Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27Nature, 1983
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970